Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy

Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy: A12 Month Multimodal Imaging Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07526857

Acronym

GLIA-MAC

Enrollment

Registered

2026-04-13

Start date

2025-01-01

Completion date

2026-01-01

Last updated

2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy, DR

Brief summary

The aim of the study is to evaluate in diabetic patients affected by diabetic retinopathy epivascular glia regression and macular pigment restoration after faricimab injection in diabetic retinopathy in a 1 year follow up

Interventions

DRUGFaricimab Injection [Vabysmo]

One group treated with faricimab and the other one treated with Aflibercept

DRUGAflibercept (2.0 mg)

Aflibercept 2 mg intravitreal injection

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* diagnosis of diabetic macular edema, diabetic retinopathy

Exclusion criteria

* previous ocular surgery, history of vitreoretinal and/or retinal vascular diseases, uveitis, myopia over 6 dioptres, significant corneal and/or lens opacity, glaucoma, ocular MNV related to other causes than nAMD, geographic atrophy, subretinal fibrosis, previous treatments for MNV

Design outcomes

Primary

Measure	Time frame	Description
Epivascular glia regression	From January 2025 to January 2026	Epivascular glia regression
Macular pigment changes	From January 2025 to January 2026	Macular pigment changes

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026